Immunogenicity and Efficacy of Intramuscular Replication-Defective and Subunit Vaccines against Herpes Simplex Virus Type 2 in the Mouse Genital Model

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Delagrave, Simon ^a   Hernandez, Hector ^a   Zhou, Changhong ^a   Hamberger, John F ^a   Mundle, Sophia T ^a   Catalan, John ^a   Baloglu, Simge ^a,b   Anderson, Stephen F ^a   DiNapoli, Joshua M ^a   Londoño Hayes, Patricia ^a   Parrington, Mark ^a   Almond, Jeffrey ^a   Kleanthous, Harry ^a  

^a SANOFI PASTEUR   (France)

^b Momenta Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAM 529; GLYCOPROTEIN D; HERPES SIMPLEX VACCINE; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE DOSAGE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; LIMIT OF DETECTION; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; SPINAL GANGLION; SPLEEN CELL; TREND STUDY; VAGINA MUCOSA; VIRUS GENOME; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS SHEDDING;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; FEMALE; GANGLIA, SPINAL; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; HUMANS; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; VACCINES, ATTENUATED; VACCINES, SUBUNIT; VAGINA; VIRAL ENVELOPE PROTEINS;

EID: 84867432478     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046714     Document Type: Article

References (33)

1. Gupta R, Warren T, Wald A, (2007) Genital herpes. Lancet 370: 2127-2137 doi:10.1016/S0140-6736(07)61908-4.
2. Schiffer JT, Corey L, (2009) New concepts in understanding genital herpes. Curr Infect Dis Rep 11: 457-464.
3. Looker KJ, Garnett GP, Schmid GP, (2008) An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ 86: 805-812, A.
4. Fisman DN, Lipsitch M, Hook EW, Goldie SJ, (2002) Projection of the future dimensions and costs of the genital herpes simplex type 2 epidemic in the United States. Sex Transm Dis 29: 608-622.
5. Stanberry LR, (2004) Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 11 (Suppl 3):: 161A-169A.
6. Bernstein DI, Aoki FY, Tyring SK, Stanberry LR, St-Pierre C, et al. (2005) Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis 40: 1271-1281 doi:10.1086/429240.
7. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, et al. (2002) Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 347: 1652-1661 doi:10.1056/NEJMoa011915.
8. Belshe R, Leone P, Bernstein DI, Wald A, Levin MJ, et al. (2012) Efficacy Results of a Trial of a Herpes Simplex Vaccine. N Engl J Med 366: 34-43.
9. Johnston C, Koelle DM, Wald A, (2011) HSV-2: in pursuit of a vaccine. J Clin Invest 121: 4600-4609 doi:10.1172/JCI57148.
10. Halford WP, Püschel R, Gershburg E, Wilber A, Gershburg S, et al. (2011) A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PLoS ONE 6: e17748 doi:10.1371/journal.pone.0017748.
11. Prichard MN, Kaiwar R, Jackman WT, Quenelle DC, Collins DJ, et al. (2005) Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine 23: 5424-5431 doi:10.1016/j.vaccine.2005.02.028.
12. Akhrameyeva NV, Zhang P, Sugiyama N, Behar SM, Yao F, (2011) Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice. J Virol 85: 5036-5047 doi:10.1128/JVI.02548-10.
13. Cattamanchi A, Posavad CM, Wald A, Baine Y, Moses J, et al. (2008) Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clin Vaccine Immunol 15: 1638-1643 doi:10.1128/CVI.00167-08.
14. Awasthi S, Lubinski JM, Shaw CE, Barrett SM, Cai M, et al. (2011) Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone. J Virol 85: 10472-10486 doi:10.1128/JVI.00849-11.
15. Koelle DM, Magaret A, McClurkan CL, Remington ML, Warren T, et al. (2008) Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naïve and HSV-2-infected subjects. Clin Vaccine Immunol 15: 773-782 doi:10.1128/CVI.00020-08.
16. Mo A, Musselli C, Chen H, Pappas J, Leclair K, et al. (2011) A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy. Vaccine 29: 8530-8541 doi:10.1016/j.vaccine.2011.07.011.
17. Tirabassi RS, Ace CI, Levchenko T, Torchilin VP, Selin LK, et al. (2011) A mucosal vaccination approach for herpes simplex virus type 2. Vaccine 29: 1090-1098 doi:10.1016/j.vaccine.2010.11.076.
18. Da Costa X, Kramer MF, Zhu J, Brockman MA, Knipe DM, (2000) Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J Virol 74: 7963-7971.
19. Da Costa XJ, Jones CA, Knipe DM, (1999) Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc Natl Acad Sci USA 96: 6994-6998.
20. Hoshino Y, Dalai SK, Wang K, Pesnicak L, Lau TY, et al. (2005) Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol 79: 410-418 doi:10.1128/JVI.79.1.410-418.2005.
21. Hoshino Y, Pesnicak L, Dowdell KC, Burbelo PD, Knipe DM, et al. (2009) Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J Infect Dis 200: 1088-1095 doi:10.1086/605645.
22. Bourne N, Bravo FJ, Francotte M, Bernstein DI, Myers MG, et al. (2003) Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J Infect Dis 187: 542-549 doi:10.1086/374002.
23. Siegrist C-A (2008) The Immunology of Vaccination. In: Plotkin SA, Orrenstein WA, Offit PA, editors. Vaccines. Elsevier Inc.
24. Knuf M, Zepp F, Meyer CU, Habermehl P, Maurer L, et al. (2010) Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months. Eur J Pediatr 169: 925-933 doi:10.1007/s00431-010-1142-6.
25. de Bruyn G, Vargas-Cortez M, Warren T, Tyring SK, Fife KH, et al. (2006) A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 24: 914-920 doi:10.1016/j.vaccine.2005.08.088.
26. Brockman MA, Verschoor A, Zhu J, Carroll MC, Knipe DM, (2006) Optimal long-term humoral responses to replication-defective herpes simplex virus require CD21/CD35 complement receptor expression on stromal cells. J Virol 80: 7111-7117 doi:10.1128/JVI.01421-05.
27. Tengvall S, Lundqvist A, Eisenberg RJ, Cohen GH, Harandi AM, (2006) Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J Virol 80: 5283-5291 doi:10.1128/JVI.02013-05.
28. Awasthi S, Zumbrun EE, Si H, Wang F, Shaw CE, et al. (2012) Live Attenuated Herpes Simplex Virus Type 2 Glycoprotein E Deletion Mutant as a Vaccine Candidate Defective in Neuronal Spread. J Virol doi:10.1128/JVI.07203-11.
29. Khodai T, Chappell D, Christy C, Cockle P, Eyles J, et al. (2011) Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models. Clin Vaccine Immunol 18: 1702-1709 doi:10.1128/CVI.05071-11.
30. Morrison LA, Knipe DM, (1997) Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1. Virology 239: 315-326 doi:10.1006/viro.1997.8884.
31. Milligan GN, Bernstein DI, Bourne N, (1998) T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J Immunol 160: 6093-6100.
32. Byers AM, Tapia TM, Sassano ER, Wittman V, (2009) In vitro antibody response to tetanus in the MIMIC system is a representative measure of vaccine immunogenicity. Biologicals 37: 148-151 doi:10.1016/j.biologicals.2009.02.018.
33. Malin SA, Davis BM, Molliver DC, (2007) Production of dissociated sensory neuron cultures and considerations for their use in studying neuronal function and plasticity. Nat Protoc 2: 152-160 doi:10.1038/nprot.2006.461.